Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.82 |
| ▸ | GRM6 | O15303 | 2/20 | 0.82 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.82 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.82 |
| ▸ | GSR | P00390 | 2/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.82 |
| ▸ | GRM5 | P41594 | 1/20 | 0.82 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.82 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.82 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.82 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.82 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.82 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.82 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.82 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.82 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542836 | 1.00 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GSR | |
| SCHEMBL542624 | 1.00 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GSR | |
| SCHEMBL27950028 | 1.00 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GSR | |
| SCHEMBL29373318 | 1.00 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL5704264 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL1554237 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL410241 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1330824 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL17127348 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1330484 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020137172-A1 | METHOD FOR DIAGNOSING INTERSTITIAL CYSTITIS | 公立大学法人奈良県立医科大学 | 2020-07-02 | — | — | WO | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-11659854-B2 | Method for imparting body taste to food | FUJI OIL HOLDINGS INC. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| EP-3918603-A1 | PREDICTING BLOOD METABOLITES | Yeda Research and Development Co. Ltd (IL) | 2021-12-08 | — | — | EP | disclosed |
| EP-3912481-A1 | EDIBLE OIL/FAT COMPOSITION AND METHOD FOR PRODUCING SAME | Fuji Oil Holdings Inc. (JP) | 2021-11-24 | — | — | EP | disclosed |
| CN-113316395-A | Edible oil and fat composition and method for producing same | 不二制油集团控股株式会社 | 2021-08-27 | — | — | CN | disclosed |
| US-20210223270-A1 | METHOD FOR DIAGNOSING INTERSTITIAL CYSTITIS | PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY (JP) | 2021-07-22 | — | — | US | disclosed |
| WO-2020149287-A1 | EDIBLE OIL/FAT COMPOSITION AND METHOD FOR PRODUCING SAME | 不二製油グループ本社株式会社 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020137172-A1 | METHOD FOR DIAGNOSING INTERSTITIAL CYSTITIS | 公立大学法人奈良県立医科大学 | 2020-07-02 | — | — | WO | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| CN-101888777-A | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors | BIPAR SCIENCES INC | 2010-11-17 | — | — | CN | disclosed |
| US-20090149397-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS | BIPAR SCIENCES | 2009-06-11 | — | — | US | disclosed |
| US-20080319054-A1 | Treatment of Cancer | BIPAR SCIENCES, INC. | 2008-12-25 | — | — | US | disclosed |
| US-7405227-B2 | Treatment of cancer | BIPAR SCIENCES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1906948-A2 | TREATMENT OF CANCER | Bipar Sciences, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007011962-A2 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015837-A1 | Treatment of Cancer | BIPAR SCIENCES, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319054-A1 | Treatment of Cancer | PARP1, PARP2, PARP3 | GRM8 4450/4885GRM6 3660/4885GRM7 3975/4885 |
| US-20090149397-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS | TOP1, PARP1, PARP2 | GRM8 4795/4885GRM6 4553/4885GRM7 4535/4885 |
| US-20070015837-A1 | Treatment of Cancer | PARP1, PARP2, PARP3 | GRM8 4450/4885GRM6 3660/4885GRM7 3975/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | GRM8 1440/4885GRM6 1039/4885GRM7 698/4885 |
| US-20080103104-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | GRM8 4450/4885GRM6 3660/4885GRM7 3975/4885 |
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | GRM8 4450/4885GRM6 3660/4885GRM7 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.